FDA requiring labeling changes for benzodiazepines

FDA is requiring an update to the Boxed Warning, its most prominent safety warning, and requiring class-wide labelling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions to help improve their safe use.

Source:

US Food and Drug Administration